Cite
APA Citation
Furze, R. C., Molnar, J., Parr, N. J., Ahmad, F., Henry, Y., Howe, D., Singh, R., Toal, M., Bassil, A. K., Bernard, S. G., Davis, R. P., Gibson, A., Maller, N. C., Sharp, C., Tough, D. F., Prinjha, R. K., & Lewis, H. D. (2022). phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia. British journal of clinical pharmacology, 88(12), 5238–5256. http://access.bl.uk/ark:/81055/vdc_100172530149.0x000045